Search results
Results from the WOW.Com Content Network
T cells are a type of cell that helps the immune system fight cancer and infections. [3] Lifileucel is the first tumor-derived T cell immunotherapy approved by the US Food and Drug Administration (FDA). [3] It was approved for medical use in the United States in February 2024. [2] [4]
Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [ 16 ] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [ 17 ]
Treatment of adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Repotrectinib
Nivolumab (Opdivo) was developed by Bristol-Myers Squibb and first approved by the FDA in 2014 for the treatment of melanoma. It was later approved for squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma.
For premium support please call: 800-290-4726 more ways to reach us
The agency's greenlight for the first cell therapy targeting a solid tumor allows use in patients who have been previously treated with other therapies, but their cancer has spread to other parts ...
2010 – The first autologous cell-based cancer vaccine, Provenge, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer. 2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma; 2011 – Carl H. June reports first successful use of ...
The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular ...